Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

The Apostolic Church of Jesus Christ held a Sickle Cell blood drive Saturday, to help those affected with the condition.

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...

Symptom scores remained stable over time, with similar QOL trends in both treatment arms.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

For the past month, local basketball programs have teamed up to raise awareness and spread hope for 9-year-old Autumn and ...

In a recent study, non-invasive prenatal testing was able to help researchers diagnose fetal anemia earlier during pregnancy.